CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer

Abstract Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and of splice factor kinases that regulate spl...

Full description

Bibliographic Details
Main Authors: Simon Uzor, Sean R. Porazinski, Ling Li, Bethany Clark, Masahiko Ajiro, Kei Iida, Masatoshi Hagiwara, Abdullah A. Alqasem, Claire M. Perks, Ian D. Wilson, Sebastian Oltean, Michael R. Ladomery
Format: Article
Language:English
Published: Nature Portfolio 2021-04-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-86908-6